S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
BREAKING: Tiny biotech successfully treats blindness (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
BREAKING: Tiny biotech successfully treats blindness (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
BREAKING: Tiny biotech successfully treats blindness (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
BREAKING: Tiny biotech successfully treats blindness (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NYSE:KEY

KeyCorp - KEY Earnings Date, Estimates & Call Transcripts

$12.49
+0.63 (+5.31%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$12.12
$12.98
50-Day Range
$11.27
$20.05
52-Week Range
$9.60
$23.95
Volume
26.65 million shs
Average Volume
20.39 million shs
Market Capitalization
$11.64 billion
P/E Ratio
6.51
Dividend Yield
6.57%
Price Target
$19.55

Earnings Summary

Upcoming
Earnings Date
Apr. 20Estimated
Actual EPS
(Jan. 19)
$0.38 Missed By -$0.17
Consensus EPS
(Jan. 19)
$0.55
Last Year's Q1 EPS
(1/20/2022)
$0.64
Skip Charts & View Estimated and Actual Earnings Data

KEY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KEY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

KeyCorp Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20235$0.42$0.57$0.49
Q2 20233$0.36$0.61$0.51
Q3 20233$0.36$0.63$0.53
Q4 20233$0.40$0.66$0.56
FY 202314$1.54$2.47$2.09
Q1 20243$0.55$0.61$0.57
Q2 20243$0.54$0.66$0.59
Q3 20243$0.55$0.67$0.60
Q4 20241$0.63$0.63$0.63
FY 202410$2.27$2.57$2.39

KEY Earnings Date and Information

KeyCorp last released its quarterly earnings data on January 19th, 2023. The financial services provider reported $0.38 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.55 by $0.17. The firm earned $1.89 billion during the quarter, compared to analyst estimates of $1.93 billion. KeyCorp has generated $1.92 earnings per share over the last year ($1.92 diluted earnings per share) and currently has a price-to-earnings ratio of 6.5. Earnings for KeyCorp are expected to grow by 12.06% in the coming year, from $1.99 to $2.23 per share. KeyCorp has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 20th, 2023 based off prior year's report dates.

KeyCorp Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/20/2023
(Estimated)
        
1/19/2023Q4 2022$0.55$0.38($0.17)$0.38$1.93 billion$1.89 billion    
10/20/2022Q3 2022$0.59$0.55($0.04)$0.55$1.88 billion$1.88 billion    
7/21/2022Q2 2022$0.52$0.54+$0.02$0.54$1.76 billion$1.79 billion    
4/21/2022Q1 2022$0.48$0.45($0.03)$0.45$1.74 billion$1.70 billion    
1/20/2022Q4 2021$0.57$0.64+$0.07$0.64$1.80 billion$1.95 billion    
10/21/20219/30/2021$0.57$0.65+$0.08$0.65$1.74 billion$1.82 billion    
7/19/20216/30/2021$0.54$0.73+$0.19$0.71$1.73 billion$1.77 billion    
4/19/20213/31/2021$0.48$0.61+$0.13$0.61$1.68 billion$1.75 billion  
1/20/202112/31/2020$0.43$0.57+$0.14$0.55$1.71 billion$1.84 billion  
10/21/20209/30/2020$0.36$0.41+$0.05$0.41$1.68 billion$1.69 billion  
7/22/20206/30/2020$0.09$0.16+$0.07$0.15$1.59 billion$1.72 billion  
4/16/20203/31/2020$0.18$0.12($0.06)$0.12$1.55 billion$1.47 billion  
1/23/2020Q4 2019$0.48$0.48$0.51$1.65 billion$1.64 billion  
10/17/20199/30/2019$0.46$0.48+$0.02$0.57$1.64 billion$1.63 billion  
7/23/20196/30/2019$0.44$0.44$0.48$1.62 billion$1.61 billion  
4/18/20193/31/2019$0.42$0.40($0.02)$0.42$1.60 billion$1.52 billion  
1/17/2019Q4 2018$0.47$0.48+$0.01$0.51$1.63 billion$1.65 billion
10/18/20189/30/2018$0.44$0.45+$0.01$0.45$1.64 billion$1.60 billion
7/19/2018Q2 2018$0.42$0.44+$0.02$0.44$1.60 billion$1.65 billion
4/19/2018Q1 2018$0.38$0.38$0.38$1.56 billion$1.55 billion
1/18/2018Q4 2017$0.36$0.36$0.55$1.58 billion$1.59 billion  
10/19/2017Q3 2017$0.35$0.35$0.38$1.56 billion$1.55 billion
7/20/2017Q2 2017$0.34$0.34$0.32$1.53 billion$1.64 billion
4/20/2017Q1 2017$0.2820$0.32+$0.0380$0.37$1.47 billion$1.51 billion
1/19/2017Q416$0.29$0.31+$0.02$0.43$1.45 billion$1.56 billion
10/25/2016Q316$0.26$0.30+$0.04$0.44$1.28 billion$1.34 billion  
7/26/2016Q216$0.27$0.27$0.31$1.09 billion$1.07 billion  
4/21/2016Q116$0.25$0.24($0.01)$0.26$1.06 billion$1.04 billion  
1/21/2016Q415$0.28$0.27($0.01)$0.30$1.09 billion$1.10 billion  
10/15/2015Q315$0.27$0.26($0.01)$0.29$1.05 billion$1.07 billion  
7/16/2015Q215$0.28$0.27($0.01)$0.27$1.05 billion$1.08 billion  
4/16/2015Q115$0.26$0.26$0.26$1.03 billion$1.01 billion
1/22/2015Q414$0.26$0.28+$0.02$0.30$1.04 billion$1.07 billion
10/15/2014Q314$0.26$0.26$0.29$1.04 billion$998.00 million  
7/17/2014Q214$0.25$0.27+$0.02$0.30$1.02 billion$1.03 billion
4/17/2014Q114$0.24$0.26+$0.02$0.26$1.01 billion$1,000.00 million  
1/23/2014Q4 2013$0.24$0.26+$0.02$0.27$1.03 billion$1.04 billion
10/16/2013Q3 2013$0.22$0.25+$0.03$0.21$1.02 billion$1.04 billion  
7/18/2013Q2 2013$0.20$0.21+$0.01$0.20$1.02 billion$1.02 billion
4/18/2013Q1 2013$0.20$0.21+$0.01$0.21$1.03 billion$1.01 billion  
1/24/2013Q4 2012$0.22$0.21($0.01)$1.06 billion$1.07 billion  
10/18/2012$0.21$0.23+$0.02
7/19/2012$0.18$0.23+$0.05
4/19/2012$0.19$0.21+$0.02
1/24/2012$0.21$0.21
10/20/2011$0.21$0.24+$0.03
7/19/2011$0.20$0.26+$0.06
4/18/2011$0.16$0.25+$0.09
1/25/2011$0.13$0.33+$0.20  
10/22/2010Q3 2010$0.03$0.19+$0.16$0.18
7/22/2010Q2 2010($0.11)$0.06+$0.17$0.09
4/21/2010Q1 2010($0.29)($0.11)+$0.18($0.11)
1/21/2010Q4 2009($0.39)($0.39)($0.48)
10/21/2009Q3 2009($0.39)($0.47)($0.08)($0.42)
7/22/2009Q2 2009($0.41)($0.69)($0.28)($0.70)
4/21/2009Q1 2009($0.20)($0.83)($0.63)($0.57)
1/22/2009Q4 2008($0.02)($0.48)($0.46)$0.17
10/21/2008Q3 2008$0.16($0.10)($0.26)($0.10)
7/22/2008Q2 2008($2.49)($2.70)($0.21)($2.70)
4/17/2008Q1 2008$0.35$0.29($0.06)$0.03
1/22/2008Q4 2007($0.03)$0.06+$0.09$0.06












KeyCorp Earnings - Frequently Asked Questions

When is KeyCorp's earnings date?

KeyCorp has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 20th, 2023 based off last year's report dates. Learn more on KEY's earnings history.

Did KeyCorp beat their earnings estimates last quarter?

In the previous quarter, KeyCorp (NYSE:KEY) missed the analysts' consensus estimate of $0.55 by $0.17 with a reported earnings per share (EPS) of $0.38. Learn more on analysts' earnings estimate vs. KEY's actual earnings.

How can I listen to KeyCorp's earnings conference call?

The conference call for KeyCorp's latest earnings report can be listened to online. Listen to Conference Call

How can I read KeyCorp's conference call transcript?

The conference call transcript for KeyCorp's latest earnings report can be read online. Read Transcript

How much revenue does KeyCorp generate each year?

KeyCorp (NYSE:KEY) has a recorded annual revenue of $8.13 billion.

How much profit does KeyCorp generate each year?

KeyCorp (NYSE:KEY) has a recorded net income of $1.92 billion. KEY has generated $1.92 earnings per share over the last four quarters.

What is KeyCorp's price-to-earnings ratio?

KeyCorp (NYSE:KEY) has a trailing price-to-earnings ratio of 6.51 and a forward price-to-earnings ratio of 6.28. The price/earnings-to-growth ratio is 1.

What is KeyCorp's EPS forecast for next year?

KeyCorp's earnings are expected to grow from $1.99 per share to $2.23 per share in the next year, which is a 12.06% increase.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NYSE:KEY) was last updated on 3/28/2023 by MarketBeat.com Staff